Investment Rating - The report maintains an "Outperform" rating for the company [1][8] Core Views - The company is increasing its investment in R&D and sales, which is expected to impact short-term profitability. The focus is on expanding indications for growth hormone and developing new pipelines [1][8] - The revenue forecast for 2024 is adjusted to RMB 13.47 billion, reflecting a decrease of 7.55%, with net profit expected to be RMB 2.58 billion, down 43.01% [8] - The target price is adjusted to RMB 107.53, based on a 2025 PE of 16X, reflecting a valuation discount compared to peers due to intensified competition in the growth hormone market [1][8] Financial Summary - The company reported a revenue of RMB 14.57 billion in 2023, with a projected decline to RMB 13.47 billion in 2024. The net profit for 2023 was RMB 4.53 billion, expected to drop to RMB 2.58 billion in 2024 [3][5] - The EPS forecast for 2025 is adjusted to RMB 6.72, with a new forecast for 2027 at RMB 7.49 [1][8] - The company's profit margin is declining due to increased R&D and sales expenses, as well as management costs associated with restructuring [8] Segment Performance - The core subsidiary, Jinsai, is expected to generate revenue of RMB 10.67 billion in 2024, down 3.73%, with a net profit of RMB 2.68 billion, a decrease of 40.67% [8] - The sales of the shingles vaccine from the Bick segment are projected to decline, with revenue expected to be RMB 1.23 billion in 2024, down 32.64% [8] - Ongoing R&D projects are progressing, with milestones achieved in various vaccine developments [8]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of 60.68 RMB per share, reflecting a potential upside from the current price of 47.47 RMB [1][8]. Core Insights - The company has demonstrated steady revenue growth, with a notable performance in recurring net profit attributable to shareholders (NPAtS), which surged nearly 60% in 2024. The education business has rebounded with over 20% growth following a decline in 2023, while smart automotive and open platform businesses have also excelled. The continuous upgrade of foundational AI models is expected to further solidify the company's leadership in the AI sector [1][8]. Financial Summary - In 2024, the company achieved a revenue of 23.34 billion RMB, representing an 18.79% year-over-year increase. The net profit attributable to shareholders was 560 million RMB, down 14.78% year-over-year, while the recurring NPAtS reached 188 million RMB, up 59.36% year-over-year. For Q1 2025, revenue was 4.66 billion RMB, up 27.74% year-over-year, with a net profit attributable to shareholders of -193 million RMB [3][8]. - Revenue forecasts for 2025 and 2026 are set at 28.06 billion RMB and 33.80 billion RMB, respectively, with a new forecast for 2027 at 41.03 billion RMB. The company is expected to maintain a strong revenue growth rate despite its large revenue base [1][8]. Business Performance - The company's various business segments showed significant growth in 2024, with smart education revenue reaching 7.23 billion RMB (up 29.94%), open platform revenue at 5.17 billion RMB (up 31.33%), and smart automotive revenue at 0.99 billion RMB (up 42.16%). The GBC synergy model has effectively driven the growth of the education business, providing tailored solutions in 85 cities/counties [3][8]. - The Spark foundational model has become a crucial growth driver, leading in project awards in 2024. The model was upgraded in April 2024, achieving performance comparable to industry leaders while maintaining a smaller parameter size [1][8].

Investment Rating - Rating: Overweight [1] Core Viewpoints - The launch of Harmony PC enhances Huawei's '1+8+N' strategy, positioning it to lead in the AI era and the Internet of Everything [4][6] - Harmony PC reconstructs the OS from the kernel, with a focus on performance, security, and distributed features [7] - Harmony OS ecosystem has surpassed 1 billion devices, with over 7.2 million developers and more than 20,000 native applications [9] Summary by Sections Investment Recommendations - Recommended targets include Chinasoft International, Isoftstone Information Technology, Newland Digital Technology, Jiangsu Hoperun Software, and Talkweb Information System; related targets include Beijing Oriental Jicheng, Jwipc Technology Co., Ltd., and Shijiazhuang ChangShan BeiMing Technology [4][6] Harmony OS Development - Harmony OS is built on a robust foundation with the Harmony kernel, Ark Engine for performance enhancement, and a distributed architecture for resource sharing [7] - The ecosystem includes over 2000 integrated applications, with 150+ dedicated PC applications already adapted [4][9] AI and IoT Integration - Harmony AI sets a new standard for smart computing, enabling system-level assistants and efficient collaboration across devices [8] - Harmony PC supports over 1000 peripheral devices, breaking hardware barriers and enhancing user experience [8] Ecosystem Growth - Huawei's ecosystem has reached over 1 billion devices, supported by a significant investment in the Harmony Ecosystem Partner Program [9] - The dual-track strategy allows compatibility with mainstream Windows applications, reducing user migration costs [9]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 46.67, compared to the current price of RMB 40.13 [1][8]. Core Insights - In 2024, the company is projected to achieve revenue of RMB 2.87 billion (+0.96%) and a net profit attributable to shareholders of RMB 501 million (+0.20%). The recurring net profit attributable to shareholders is expected to be RMB 496 million (+3.18%) [8]. - The company is adjusting its EPS forecasts for 2025 and 2026 to RMB 1.26 and RMB 1.36, respectively, and adding a forecast for 2027 of RMB 1.49. The 2025 PE is set at 37X [8]. - The dental implant segment shows strong performance, while orthodontics is under short-term pressure due to consumption downgrade. By the end of 2024, the company will have over 260,000 sqm of medical service area and 3.53 million outpatient visits [8]. - The company has completed five major dental clusters in Zhejiang province and is expanding its "regional main hospital + branch" model [8]. Financial Summary - The company’s revenue and net profit projections for the coming years are as follows: - 2023A: Revenue of RMB 2.85 billion, Net Profit of RMB 500 million - 2024A: Revenue of RMB 2.87 billion, Net Profit of RMB 501 million - 2025E: Revenue of RMB 3.00 billion, Net Profit of RMB 564 million - 2026E: Revenue of RMB 3.20 billion, Net Profit of RMB 609 million - 2027E: Revenue of RMB 3.40 billion, Net Profit of RMB 665 million [4][5]. - The company’s net asset return rate is projected to be around 12.9% for 2025 and 13.0% for 2027 [5]. Business Expansion Strategy - The company is shifting its provincial expansion strategy from traditional self-built models to a combination of acquisitions and asset-light franchising, aiming for a national network at lower costs and higher efficiency [8]. - The company has opened 44 Dandelion branches in 2024, with 60% achieving break-even, and plans to open additional branches in 2025 [8].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 24.18, compared to the current price of RMB 20.89 [1][9]. Core Views - The company is exploring growth drivers across four major business areas, with a focus on chronic disease management and infectious disease testing. The revenue for 2024 is projected to be RMB 3.07 billion, representing a growth of 10.85%, while the net profit attributable to shareholders is expected to reach RMB 562 million, an increase of 15.18% [1][9][10]. - The report highlights breakthroughs in luminescence, molecular diagnostics, and pathology, with significant advancements in product performance and market access, particularly in non-U.S. overseas markets [11][12]. Financial Summary - The financial projections indicate a revenue increase from RMB 2,765 million in 2023 to RMB 3,065 million in 2024, with a year-on-year growth of 10.8%. Net profit is expected to rise from RMB 488 million in 2023 to RMB 562 million in 2024, reflecting a growth of 15.2% [3][9]. - Earnings per share (EPS) forecasts have been adjusted to RMB 1.34 for 2025 and RMB 1.57 for 2026, with a new forecast of RMB 1.82 for 2027 [9][10]. Business Performance - In the infectious disease testing segment, revenue is projected to be RMB 1.04 billion in 2024, a growth of 9.50%. The chronic disease management segment is expected to generate RMB 1.37 billion, marking a significant increase of 22.38% [10]. - The company has established a robust international sales team, exporting products to over 150 countries, which has contributed to rapid growth in non-U.S. markets [12].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 27.86, compared to the current price of RMB 21.90 [1][8]. Core Insights - The company expects 2024 revenue of RMB 2.66 billion, representing a 14.00% year-over-year increase, and a net profit attributable to shareholders of RMB 745 million, which is a 21.76% increase [8]. - The company is actively expanding its plasma collection capacity, with 19 stations, 17 of which are operational, and anticipates plasma collection to exceed 1,400 tons in 2024, showing rapid growth [8]. - The report highlights ongoing R&D efforts, with a total of 11 product types expected by the end of 2024 and over 10 products in fast-track development, including clinical trials for new products [8]. Financial Summary - For 2023, the company reported revenue of RMB 2,329 million, with a projected increase to RMB 2,655 million in 2024, and further growth to RMB 3,090 million in 2025 [3][5]. - Net profit attributable to shareholders is expected to rise from RMB 612 million in 2023 to RMB 745 million in 2024, and to RMB 886 million in 2025 [3][5]. - The report adjusts the EPS forecast for 2025 to RMB 1.21 and for 2026 to RMB 1.39, with a new forecast for 2027 set at RMB 1.56 [8]. Market Position and Strategy - The company is pursuing both organic growth and external expansion strategies, with significant investments in capacity expansion expected to exceed 3,000 tons annually post-expansion [8]. - The report notes the company's efforts in short-term export sales and ongoing regulatory registration for overseas markets, including sales in Pakistan and potential opportunities in Brazil [8].

Investment Rating - The report maintains an "Outperform" rating for JD Health International [2][18]. Core Insights - JD Health's Q1 2025 revenue reached a record high of RMB 16.65 billion, reflecting a year-over-year increase of 25.5% and a quarter-over-quarter increase of 0.8%, surpassing the full-year guidance [3][14]. - The revenue growth is attributed to increased demand during the influenza season, growth in high-value original drugs, and higher sales of health supplements due to increased advertising investments [15]. - The company achieved an operating profit of RMB 1.07 billion, a significant increase of 119.8%, with an operating margin of 6.4%, contributing to a net profit growth of 47.7% [15][18]. - JD Health plans to focus on self-operated on-demand drug delivery in 10 key cities in 2025, leveraging a hybrid B2C+O2O strategy to enhance customer stickiness and operational efficiency [4][16]. Financial Performance and Forecast - Revenue forecasts for FY25 and FY26 are RMB 66.6 billion and RMB 75.7 billion, representing year-over-year growth of 14.5% and 13.7% respectively [5][18]. - Adjusted net profit is projected at RMB 4.4 billion for FY25, reflecting a decrease of 7.3%, and RMB 5.4 billion for FY26, indicating an increase of 20.5% [5][18]. - The report estimates a P/E ratio of 26x for FY25 and 21x for FY26, indicating a favorable valuation based on the company's fundamentals [5][18]. Valuation - The DCF model estimates the equity value of JD Health at HKD 136.8 billion, corresponding to a target price of HKD 42.90 per share [8][9].

Investment Rating - The investment rating for JD Logistics is maintained at "Outperform" [2][5]. Core Views - JD Logistics reported Q1 2025 results with revenue of RMB 46.97 billion, reflecting a year-on-year growth of 11.5%, and a Non-IFRS net profit of RMB 0.751 billion, up 13.4% year-on-year [3][10]. - The company is expected to achieve total revenue of RMB 203.3 billion in 2025, representing an 11.2% increase, with a Non-IFRS net profit margin projected at 4.0% [11]. Financial Performance Summary - Revenue projections for JD Logistics are as follows: - 2024: RMB 182.84 billion - 2025: RMB 203.28 billion (+11%) - 2026: RMB 225.67 billion (+11%) - 2027: RMB 248.56 billion (+10%) [4][8]. - Net profit forecasts are: - 2024: RMB 7.92 billion - 2025: RMB 8.21 billion (+4%) - 2026: RMB 11.11 billion (+35%) - 2027: RMB 13.23 billion (+19%) [4][8]. - The gross profit margin (GPM) is expected to improve from 10.2% in 2024 to 13.0% by 2027 [4][8]. Market Position and Strategy - JD Logistics has strengthened its integrated supply chain services, with revenue from integrated supply chain clients reaching RMB 23.2 billion, a 13.2% increase, driven by higher revenue from JD Group and a 13.1% increase in the number of integrated supply chain clients [3][4]. - The company is investing in enhancing service quality and expanding its customer base, with a focus on improving operational efficiency and inventory management [4][5]. Valuation - The target price for JD Logistics is set at HKD 19.79, based on a 15X PE valuation for FY25E [2][11].

Investment Rating - The report assigns a rating of "Outperform" for Samsonite, indicating an expected total return over the next 12-18 months that exceeds the return of its relevant broad market benchmark [20]. Core Insights - Samsonite's 1Q25 revenue and profit performance were under pressure, with net sales declining 4.5% year-on-year to $797 million, primarily due to weak demand in North America and China, along with a high base from the previous year [2][9]. - The company aims to maintain gross margin levels despite challenges, with a gross margin of 59.4% in 1Q25, down 100 basis points year-on-year [2][9]. - Adjusted EBITDA decreased by 20.9% year-on-year, reflecting negative leverage effects from lower gross margins and sales, resulting in an adjusted EBITDA rate of 18.8% [2][9]. - Adjusted net income fell by 40.3% year-on-year, driven by the decline in adjusted EBITDA, increased depreciation, net interest expense, and a higher effective tax rate [2][9]. - The company reported a negative adjusted free cash flow of $41 million in 1Q25, attributed to the decline in EBITDA and an increase in net working capital [2][9]. Revenue Performance by Region - Sales in Asia and North America were weak, with Asia revenue down 7% year-on-year, and North America revenue declining 8% [3][10]. - European sales continued to show strong growth, with a 4.4% year-on-year increase, supported by positive growth across all core brands [3][10]. - Latin America sales remained flat year-on-year, with a notable decline in Mexico due to lower consumer confidence [3][10]. Channel Performance - The Direct-to-Consumer (DTC) channel performed well, accounting for 38.2% of revenue in 1Q25, with e-commerce contributing 10.6% and offline retail 27.5% [4][11]. - The offline retail business saw a decline of 2.6%, primarily due to reduced customer traffic, while wholesale business declined by 6.1% year-on-year [4][11]. Tariff Policy and Mitigation Strategies - The U.S. tariff policy remains unclear, causing caution among consumers and wholesale customers [5][12]. - The company has reduced its sourcing from China to 14% and plans to further decrease this by year-end, leveraging a diversified sourcing platform to mitigate potential tariff impacts [5][12]. Future Guidance - Management expects 2Q25 net sales growth to be similar to 1Q25, with net revenue guidance down mid-single digits on a constant currency basis [6][13]. - Long-term growth is anticipated to be supported by strong travel trends, despite short-term macroeconomic uncertainties affecting consumer demand [6][13].

Investment Rating - The report initiates coverage with an OUTPERFORM rating, targeting a price of HK$13.40 from a current price of HK$8.06 [2]. Core Insights - The company is focused on precision therapy with small molecules in oncology and is expected to achieve profitability in 2024, driven by significant revenue growth from licensing agreements [3][4]. - The core pipeline includes Pimicotinib, which is anticipated to submit a global NDA in 2025, with potential peak sales exceeding USD 2 billion [4][19]. - The company has a robust pipeline targeting FGFR mutations, with potential coverage for approximately 1.9 million patients globally [4][39]. Financial Projections - Revenue projections for FY24, FY25, FY26, and FY27 are RMB 504 million, RMB 595 million, RMB 420 million, and RMB 560 million respectively, with net profit expected to reach RMB 28 million in FY24 [3][8]. - The company is projected to achieve a net profit of RMB 173 million by FY27, with a significant increase in diluted EPS from RMB 0.04 in FY24 to RMB 0.25 in FY27 [3][8]. Pipeline Development - The company has advanced clinical trials for Pimicotinib, which has shown promising results in treating TGCT with an ORR of 87.5% [28]. - The pipeline includes multiple candidates targeting FGFR, with ABSK011 and ABSK061 expected to achieve peak sales of over USD 3 billion collectively [14][39]. - The oral PD-L1 inhibitor ABSK043 is positioned to capture a share of the USD 52 billion PD-(L)1 market, with a projected launch in 2030 [6][14]. Management and Team - The management team has extensive experience in drug development and commercialization, with backgrounds in leading pharmaceutical companies [11][13]. - The company emphasizes early-stage R&D, allocating over 30% of its budget to this area, which supports a pipeline of over 15 preclinical candidates [7][10]. Market Opportunity - The global market for PD-(L)1 therapies is substantial, with no approved small molecule PD-1/PD-L1 drugs currently available, indicating a significant opportunity for the company's oral PD-L1 inhibitor [6][14]. - The unmet medical needs in the treatment of cGvHD and TGCT present additional market opportunities for the company's pipeline [33][25].